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ABSTRACT 
Controlling postprandial glucose levels for diabetic patients is critical to achieve the tight glycemic control that decreases the risk for 
developing long-term micro- and macrovascular complications. Herein, we report a glucose-responsive oral insulin delivery system based on 
Fc receptor (FcRn)-targeted liposomes with glucose-sensitive hyaluronic acid (HA) shell for postprandial glycemic regulation. After oral 
administration, the HA shell can quickly detach in the presence of increasing intestinal glucose concentration due to the competitive binding 
of glucose with the phenylboronic acid groups conjugated with HA. The exposed Fc groups on the surface of liposomes then facilitate 
enhanced intestinal absorption in an FcRn-mediated transport pathway. In vivo studies on chemically-induced type 1 diabetic mice show this 
oral glucose-responsive delivery approach can effectively reduce postprandial blood glucose excursions. This work is the first demonstration 
of an oral insulin delivery system directly triggered by increasing postprandial glucose concentrations in the intestine to provide an 
on-demand insulin release with ease of administration. 
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1 Introduction 
The worldwide increase in the prevalence of diabetes mellitus is a 
serious public health burden [1, 2]. The medical management of 
diabetes centers around achieving tight control of blood glucose 
levels to prevent the long-term organ damage that is associated with 
chronic hyperglycemia [3]. To this end, patients self-administer 
insulin in a daily regimen that commonly involves subcutaneous 
injection of commercial insulin formulations [4]. For example, 
rapid-acting insulin is dosed according to carbohydrate content and 
subcutaneously injected just before or after each meal to mitigate 
postprandial glycemic excursions [3]. However, this self-dosing and 
injection of insulin is associated with a high degree of human error 
and poor patient compliance, as well as complications such as pain, 
tissue invasion, infection, and nerve damage [2, 5, 6]. To improve 
quality of life for patients with diabetes, recent efforts in the past 
decades have focused on developing alternative strategies based 
on oral, nasal, pulmonary, and transdermal delivery routes [7–13]. 
Oral insulin delivery has emerged as one of the most convenient 
administration routes [9, 14–16], and numerous insulin formulations 
have been developed to enhance oral insulin delivery efficiency by 
improving intestinal absorption and preventing insulin digestion 
[17–20]. However, current formulations cannot address the need to 
release of insulin specifically following meals, where an optimized 
oral insulin delivery system would supply insulin to the body at the 
time when it is needed. 
In this study, a glucose-responsive liposome-based strategy was 
developed for oral insulin delivery. This insulin delivery system is 
composed of a glucose-responsive phenylboronic acid conjugated 
hyaluronic acid (HA-PBA) shell and a neonatal Fc receptor (FcRn)- 
targeted liposome core loaded with insulin (Fig. 1(a)). FcRn is 
expressed in the apical region of epithelial cells in the small intestine, 
Figure 1 Schematic of the glucose-responsive oral insulin delivery system with 
glucose-sensitive HA shell for postprandial glycemic regulation. (a) Schematic of 
insulin-loaded liposomes with glucose-responsive detachable HA shell for oral 
insulin delivery triggered by an evaluated glucose concentration in the intestine 
after meals. (b) Schematic of formation and response mechanism of glucose- 
responsive HA shell. 
Address correspondence to guzhen@ucla.edu 
which can bind IgG via the Fc portion, thereby facilitating protein 
transport across the intestinal epithelium into the circulation [21]. 
This specific binding functions in a pH-dependent manner, showing 
high affinity in the apical side (pH 5.5–6.5) of the duodenal 
enterocytes but not in the basolateral side (pH 7.4) [20, 22, 23]. 
Herein, we choose human IgG Fc fragment to modify the surface of 
the liposomes for FcRn-mediated transepithelial transport [20, 22, 
24]. The PBA conjugated HA shell, which coats the liposome core 
through the boronate ester formation between PBA and catechol 
groups [25, 26] on the liposome surface, can prevent the leakage 
and digestion of insulin in the gastrointestinal tract, and additionally 
serves as a glucose-responsive moiety for on-demand insulin 
absorption. Under elevated postprandial glucose concentrations in 
the intestine that occurs during meal digestion, the HA shell detaches 
due to the competitive binding of glucose with PBA (Fig. 1(b)) [27, 
28], exposing the Fc groups which promote the intestinal absorption 
of insulin-loaded liposome core to ultimately release insulin in the 
bloodstream, reducing blood glucose levels for efficient postprandial 
glycemic regulation. 
2 Results and discussion 
The insulin-loaded liposomes (Ins-Liposomes) were prepared using 
the lipid film hydration method [29, 30]. In order to prepare 
liposomes with catechol (CA) groups on the surface, dopamine 
was first conjugated to the carboxyl groups of 1,2-distearoyl-sn- 
glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)] 
(DSPE-PEG-CM) to achieve DSPE-PEG-CA using carbodiimide 
chemistry. The successful conjugation was verified through UV–Vis 
spectra (Fig. S1 in the Electronic Supplementary Material (ESM)). 
The obtained Ins-Liposomes had an average diameter of approximately 
69 nm and a zeta potential of –2.6 mV (Fig. 2(a)). The encapsulation 
efficiency (EE) and loading capacity (LC) of insulin in Ins-Liposomes 
were determined to be 20.7% and 17.1%, respectively. Polyclonal 
IgG Fc fragments were covalently conjugated to PEG chain on the 
surface of Ins-Liposomes using maleimide-thiol chemistry to prepare 
Fc fragments-modified liposomes (Fc-Liposomes). 2-Iminothiolane 
was used to modify the Fc with thiol groups [20]. After the conjugation, 
the hydrodynamic diameter of the Fc-Liposomes increased to 77 nm, 
and the surface charge showed a minor change to –6.6 mV. The HA 
shell was further coated on the Fc-Liposome via the combination 
between PBA and catechol groups [26]. The resulting liposomes 
with HA shell (HA-Fc-Liposome) had an increased size of around 
94 nm (Fig. 2(b)). The HA-Fc-Liposome showed a significant change 
in zeta potential from –6.6 to –28.1 mV, indicating the successful 
formation of HA shell. The transmission electron microscopy (TEM) 
image revealed the core–shell structure of HA-Fc-Liposomes 
(Fig. 2(c)). Both the blank HA-Fc-Liposome and Fc-Liposome showed 
insignificant cytotoxicity towards the human intestinal epithelial 
colorectal adenocarcinoma (Caco-2) cells (Fig. S2 in the ESM). 
The HA shell was expected to not only act as a glucose-responsive 
moiety, but also prevent the leakage and digestion of insulin in 
the upper gastrointestinal tract. A quick release of insulin from 
Fc-Liposomes was observed under pH 2.5 and 7.4 at 37 °C. As shown 
in Fig. 2(d), around 50% of insulin was released within 2 h. However, 
there was negligible leakage of insulin from HA-Fc-Liposomes under 
the same conditions, which can be attributed to the HA coating. 
Importantly, insulin levels were nearly completely maintained in 
the HA-Fc-Liposome under pH 2.5, demonstrating high stability of 
this insulin carrier in the acidic conditions of the stomach [31]. 
The HA-PBA was applied to coat the surface of Fc-Liposomes 
based on the complexation between catechol and PBA through 
formation of boronate esters [26]. Due to the intramolecular 
coordination that can stabilize boronate ester formation at a 
mildly acidic condition (Fig. S3 in the ESM) [25], the boronate ester 
formation was dynamically stable in the intestine fluid (pH 5.5–8.0). 
However, this kind of boronate ester can be disrupted in the presence 
of glucose due to competitive binding of glucose with PBA [26, 28], 
thereby rendering the HA shell glucose-responsiveness. To verify 
the detachment of the HA shell under high glucose concentrations, 
the HA-Fc-Liposomes containing rhodamine-labelled HA-PBA 
(Rho-HA-PBA) were incubated in phosphate buffered saline (PBS) 
buffer with increasing glucose concentrations. As shown in Fig. 3(a), 
a marked release of Rho-HA-PBA was observed after incubation 
with 5, 10, 20, and 50 mM glucose for 30 min. The morphological 
change in TEM image and the decrease in size further verified 
that incubation with 10 mM glucose was sufficient for detachment 
of the HA shell (Figs. 2(e) and 2(f)). However, insignificant release 
Figure 2 Characterization of glucose-responsive HA-Fc-Liposomes. (a) The particle size and zeta potential of Ins-Liposome, Fc-Liposome, and HA-Fc-Liposome. 
(b) The hydrodynamic size distribution of HA-Fc-Liposome measured by dynamic light scattering (DLS). (c) TEM image of HA-Fc-Liposomes. Scale bar: 100 nm.
(d) In vitro release of insulin from Fc-Liposome and HA-Fc-Liposome under pH 7.4 or 2.5. Error bars indicate s. d. (n = 3). (e) The size distribution and (f) TEM
image of HA-Fc-Liposomes after 2 h incubation with glucose (10 mM). Scale bar is 100 nm. 
was observed from the liposomes coated with crosslinked HA shell 
(HA_CL-Fc-Liposomes) in all glucose conditions. Zeta potential 
results further validated the detachment of the HA shell and the 
subsequent exposure of Fc groups. As shown in Fig. 3(b), the surface 
charge increased from –25.9 to –9.7 mV after 30 min incubation 
with 10 mM glucose, indicating the quick release of Fc-Liposome 
core. To determine the effect of the released insulin on blood glucose, 
insulin-loaded Fc-Liposomes were collected and intravenously 
injected into the streptozotocin (STZ)-induced adult type 1 diabetic 
C57BL/6J mice (insulin dose: 5 U/kg). Fc-Liposomes were able to 
generate a hypoglycemic response (Fig. S4 in the ESM) comparable 
to that of injection of native insulin, confirming the successful release 
of bioactive insulin.  
Since the formation of boronate ester is inhibited in a strong 
acidic condition in the stomach (pH 1.2–3.0), the HA-PBA could 
not form the complexation with the catechol groups on the surface 
of the Fc-Liposome core. However, due to the protonation of surface 
groups on the Fc-Liposomes in acidic conditions, the negative surface 
charge of Fc-Liposomes was converted to a positive charge under 
pH 2.5 (Fig. S5 in the ESM), which kept the intact HA shell by 
electrostatic interaction. Taken together, the HA shell was shown to 
prevent the leakage and digestion of insulin in the stomach. 
In vitro transepithelial transport efficiency of insulin-loaded 
liposomes was next evaluated using the Caco-2 cell monolayer 
permeability assay [20, 32]. As shown in Fig. 3(c), fluorescein 
isothiocyanate (FITC)-labelled insulin-loaded liposomes were added 
to the apical chamber over the cell monolayer and incubated with 
or without glucose (10 mM) at 37 °C for 2 h. The transepithelial 
transport efficiency was determined by measuring the fluorescence 
intensity of FITC-labelled insulin in the basolateral chamber. Since 
FcRn is highly expressed on the surface of Caco-2 cells, higher 
transepithelial permeability of Fc-Liposomes was observed due to 
FcRn-mediated transcytosis compared to Ins-liposomes (Fig. 3(d)). 
Unlike liposomes with crosslinked HA shell (HA_CL-Fc-Liposomes), 
the co-incubation with glucose also increased the transport of HA- 
Fc-Liposomes, indicating the Fc groups were exposed after glucose- 
triggered detachment of the HA shell.  
We next assessed in vivo performance of glucose-responsive 
liposomes using STZ-induced type 1 diabetic mice. Immuno-
fluorescence stained sections showed FcRn was expressed in the 
epithelium of the intestinal villi of the duodenum of STZ-induced 
diabetic mice (Fig. S6 in the ESM). The diabetic mice were further 
divided into four groups and sequentially administered by oral 
gavage: 1) Fc-Liposome + glucose; 2) HA-Fc-Liposome; 3) HA-Fc- 
Liposome + glucose; and 4) HA_CL-Fc-Liposome + glucose. Oral 
intake of glucose solution (1 g/kg) post 30 min oral intake of liposome 
was used to simulate the postprandial condition [33, 34]. Duodenum 
sections were collected and imaged 2 h after administration using 
fluorescence microscopy. As shown in Fig. 4(a), the green fluorescence 
of FITC-labelled insulin was ubiquitously observed in the villi from 
the Fc-Liposome + glucose-treated groups yet rarely observed in 
the mice treated with HA-Fc-Liposome. Moreover, the additional 
intake of glucose solution led to the obvious distribution of FITC 
fluorescence in the villi from the mice treated HA-Fc-Liposome + 
glucose. There was little fluorescence signal found in the section from 
HA_CL-Fc-Liposome + glucose-treated mice, as expected. Quantitative 
data further indicated oral administration of HA-Fc-Liposome + 
glucose resulted in a 5-fold increase in the amount of FITC-labelled 
insulin in the villi on the basolateral side of the epithelial cells 
compared to the HA_CL-Fc-Liposome + glucose-treated group 
(Fig. 4(b)). 
The blood glucose lowering generated by oral administration 
of insulin-loaded liposomes with or without Fc was assessed on 
diabetic mice (insulin dose: 10 U/kg). Oral intake of Fc-Liposomes 
induced a significant decline in blood glucose levels during the first 
12 h after treatment (Fig. 4(c)). However, the oral treatment with free 
Figure 3 In vitro glucose-triggered HA shell detachment from HA-Fc-Liposome and transepithelial transport. (a) In vitro detachment of Rho-HA-PBA from 
HA-Fc-Liposome or HA_CL-Fc-Liposome under different glucose concentrations under pH 6.0. Error bars indicate s. d. (n = 3). (b) The zeta-potential change of 
HA-Fc-Liposome in 0, 5, and 10 mM glucose solution over time. Error bars indicate s. d. (n = 3). (c) Schematic of in vitro transepithelial transport study using Caco-2 
cell monolayer permeability assay. (d) In vitro transepithelial transport of different insulin-loaded liposome formulations with or without 10 mM glucose. Error bars 
indicate s. d. (n = 3). **P < 0.01 (two-tailed Student’s t-test). 
insulin did not induce a hypoglycemic response, and the treatment 
of Ins-Liposomes or HA-Fc-Liposomes led to minimal reduction in 
blood glucose levels. Of note, the oral administration of HA-Fc- 
Liposomes that had been previously treated with 10 mM glucose 
also showed a significant blood glucose lowering effect, validating 
the exposed Fc improved the intestinal absorption of the liposomes 
after the glucose-triggered detachment of HA shell.  
Next, we assessed the glucose-responsive intestinal absorption 
of liposomes by oral administration of glucose solution to simulate 
the postprandial condition. Glucose solution (1 g/kg) was orally 
administered to mice 30 min after the oral administration of different 
insulin-loaded formulations. As demonstrated in Fig. 4(d), oral 
administration of glucose solution led to postprandial hyperglycemia, 
and the blood glucose levels reduced to the initial level after 8 h of 
treatment. Pre-treatment of insulin-loaded Fc-Liposomes significantly 
suppressed the postprandial elevation of blood glucose, where blood 
glucose levels returned to initial levels after 2 h of oral glucose 
treatment and remained at such reduced levels for 8 h. Treatment 
with glucose-responsive HA-Fc-Liposomes similarly exhibited a 
glucose-lowering effect due to the Fc-mediated intestinal absorption 
of insulin-loaded liposomes after the detachment of HA shell, triggered 
by the high glucose concentration in the intestine after oral glucose 
administration. However, a significant lasting postprandial increase 
of blood glucose was observed in the group administered HA_CL- 
Fc-Liposome, which further verified the blood glucose lowering 
action of this insulin delivery system was dependent on the intestinal 
glucose-triggered detachment of HA shell. Correspondingly, mice 
treated with HA-Fc-Liposomes presented a consistently higher plasma 
insulin concentration than those treated with HA_CL-Fc-Liposome 
(Fig. 4(e)). 
3 Conclusion 
Postprandial glycemic control is critical to prevent microvascular 
and macrovascular complications and maintain insulin resistance in 
people with diabetes [35]. Current management strategies to control 
Figure 4 In vivo studies for type 1 diabetes treatment. (a) Fasted STZ-induced type 1 diabetic mice were orally administered with different insulin formulations.
Glucose solution (1 g/kg) was administered post 30 min oral intake of insulin formulation (10 U/kg). The intestines were collected for sectioning and imaging 2 h after
administration. Green fluorescence indicated FITC-labelled insulin, and blue fluorescence indicated Hoechst 33342-stained nuclei. Scale bar: 20 μm. (b) Quantitative 
analysis of the fluorescence intensities in the in vivo FITC-insulin absorption. All the fluorescence intensities were normalized to the Fc-Liposome + glucose group.
Error bars indicate s. d. (n = 3). *P < 0.05 (two-tailed Student’s t-test). (c) Blood glucose levels of fasted diabetic mice after oral administration of insulin solution,
insulin-loaded Liposome, Fc-Liposome, HA-Fc-Liposome, and HA-Fc-Liposome pre-treated with glucose. Error bars indicate s. d. (n = 5). *P < 0.05 for administration 
with HA-Fc-Liposome pre-treated with glucose (10 mM) compared with HA-Fc-Liposome. (d) Blood glucose levels of fasted mice orally administered with different 
insulin formulations: 1) untreated; 2) insulin solution; 3) Fc-Liposome; 4) HA-Fc-Liposome; 5) HA_CL-Fc-Liposome. Glucose solution (1 g/kg) was orally 
administered post 30 min oral intake of insulin formulation (10 U/kg). (e) Plasma human insulin concentrations in diabetic mice after treatment. *P < 0.05 and **P <
0.01 for administration with HA-Fc-Liposome compared with HA_CL-Fc-Liposome. The black arrows indicate the oral administration of glucose solution. Error bars 
indicate s. d. (n = 5). 
postprandial glucose levels involve quantifying carbohydrates [36] 
to calculate insulin dose [37] and multiple injections of fast-acting 
insulin before or with a meal for type 1 and advanced type 2 diabetic 
patients; yet these methods are inaccurate and time-consuming, 
requiring consideration of carbohydrates quantity and distribution 
at each meal and snack. There remains a clear need to optimize the 
efficacy of prandial insulin dosing to confer the greatest protection 
from diabetic complications.  
In this work, we exploited an FcRn-targeted insulin-loaded 
liposome with a glucose-responsive detachable HA shell for 
postprandial glycemic control. The increased intestinal glucose 
concentration that occurs with digestion of a carbohydrate-containing 
meal was utilized to trigger the detachment of HA shell and subsequent 
exposure of Fc for enhancing the intestinal absorption by FcRn- 
mediated transepithelial transport. Thorough in vivo studies 
demonstrated that this “smart insulin pill” was able to regulate 
blood glucose levels in diabetic mice after oral intake of glucose 
solution simulating a meal. Furthermore, the single administration 
of HA-Fc-Liposomes did not reduce the blood glucose levels 
under fasting conditions, thereby effectively preventing the risk of 
hypoglycemia. In addition, it was reported that FcRn expression in 
the intestine of rodents is significantly down-regulated after weaning, 
while FcRn is expressed within the adult human intestine throughout 
life [38]. Therefore, the transepithelial transport for potential human 
use will be more efficient. This “food-responsive” formulation strategy 
integrating an intestinal signal trigger also has clinical potential in 
the oral delivery of other therapeutic agents for treating a variety of 
metabolic diseases [31, 39]. 
4 Experimental 
4.1 Materials 
All chemicals were purchased from Sigma-Aldrich unless otherwise 
specified and were used as received. Sodium hyaluronic acid was 
purchased from Freda Biochem Co., Ltd. (Shandong, China). 
Human recombinant insulin (Zn salt, 27.5 IU/mg) was purchased 
from Life Technology. Purified human polyclonal IgG Fc was 
purchased from Bethyl Laboratories. 1,2-Distearoyl-sn-glycero-3- 
phosphoethanolamine-N-[maleimide(polyethylene glycol)] (DSPE- 
PEG-MAL) (MW = 2,000) and DSPE-PEG-CM (MW = 2,000) were 
purchased from Laysan Bio, Inc. 
4.2 Synthesis and characterization of glucose-responsive 
HA-PBA, acrylate modified HA-PBA, and rhodamine-labelled 
HA-PBA 
Acrylate modified HA and rhodamine-labelled HA were synthesized 
following Refs. [40, 41]. 2-Aminophenylboronic was conjugated to HA 
in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (EDC) and N-hydroxysuccinimide (NHS). Briefly, 
0.5 g of HA (molecular weight: 10 kDa) was dissolved in water, 
to which EDC (0.58 g) and NHS (0.35 g) were added and stirred 
for 15 min at room temperature (RT). Then 2-aminophenylboronic 
acid hydrochloride (0.17 g) was added to the mixture and reacted 
at RT overnight. The reaction solution was thoroughly dialyzed 
against deionized (DI) water for 3 days. Then, HA-PBA was obtained 
by lyophilization and characterized by 1H NMR. The degree of 
modification was calculated to be 14.4% by comparing the ratio 
of the areas under the proton peaks at 6.91–7.40 ppm to the peak 
at 1.99 ppm. 1H NMR (400 MHz, D2O, δ): 7.40 (s, H, phenyl-H), 
7.20 (s, 2H, phenyl-H), 6.91 (s, H, phenyl-H). Acrylate modified 
HA-PBA and rhodamine-labelled HA-PBA were synthesized in a 
similar protocol. 
4.3 Synthesis and characterization of DSPE-PEG-CA  
DSPE-PEG-CM (200 mg), EDC (57.5 mg), and NHS (34.5 mg) 
were mixed and dissolved in 20 mL DI water and stirred for 30 min 
at RT. Dopamine hydrochloride (57 mg) was then added to the 
mixture and stirred for 8 h at RT. The unreacted dopamine was 
removed by dialysis against DI water for 2 days. The obtained 
DSPE-PEG-CA was lyophilized and stored at 4 °C until use. 
The successful conjugation was verified by measuring the UV–Vis 
absorption of catechol groups using a Nanodrop 2000C spectrometer 
(Thermo Scientific). 
4.4 Preparation of glucose-responsive liposomes loaded 
with insulin 
First, the insulin-loaded liposome was prepared by the lipid film 
hydration method. Briefly, a mixture of egg phosphatidylcholine 
(EPC), dioleoylphosphatidylethanolamine (DOPE), DSPE-PEG-MAL, 
DSPE-PEG-CA and cholesterol (weight ratio = 9:9:1:1:4) was 
dissolved in chloroform. The solution was evaporated dry to 
form the lipid film. The formed lipid film was hydrated with 4-(2- 
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer 
(5 mM) containing insulin (insulin:lipids, 1:1, w:w), dispersed by a 
probe-type ultrasonicator, and extruded 3 times through the membrane 
filters with the pore size of 0.45 and 0.20 μm successively. The non- 
encapsulated insulin was removed by centrifugation at 21,000 rpm 
and the resulting Ins-Liposomes were washed 3 times by PBS buffer 
containing 5 mM ethylene diamine tetraacetic acid (EDTA). The EE 
and LC of insulin in Ins-Liposomes were determined by measuring 
the amount of non-encapsulated insulin using a Coomassie Plus 
protein assay.  
Fc-Liposomes were obtained by conjugation of Fc to PEG chain 
on the surface of Ins-Liposomes using maleimide-thiol chemistry. 
Briefly, 86 μg of purified human polyclonal IgG Fc in PBS containing 
5 mM EDTA was reacted with 4.8 μL of Traut’s Reagent (0.5 mg/mL) 
for 1 h. The modified Fc was then added to the Ins-Liposomes and 
mixed for 1 h at 4 oC. The resulting Fc-Liposomes were collected by 
centrifugation at 21,000 rpm and washed with PBS buffer 3 times.  
The obtained Fc-Liposome solution was added to the HA-PBA 
solution (HA-PBA:lipids, 1:10, w:w) and mixed for 2 h. The HA-Fc- 
Liposomes were obtained by centrifugation at 21,000 rpm and 
washed with PBS buffer. The zeta potential and size distribution were 
measured on the Zetasizer (Nano ZS, Malvern). The TEM images 
of HA-Fc-Lipo were obtained on a JEOL 2000FX TEM instrument. 
The liposomes with non-glucose-responsive HA shell (HA_CL- 
Fc-Liposomes) were prepared by crosslinking HA shell via UV 
irradiation. The Fc-Liposomes were added into the acrylate modified 
HA-PBA solution (HA-PBA:lipids, 1:10, w:w) and stirred for 2 h. A 
crosslinker N,N-methylenebisacrylamide (MBA) (MBA:HA-PBA, 
1:5, w:w) and a photo-initiator Irgacure 2959 (0.1%, w:v) was then 
added to the mixture. After radical polymerization via UV radiation 
for 60 s using a BlueWave 75 UV Curing Spot Lamp (DYMAX), 
HA_CL-Fc-Liposomes were obtained by centrifugation at 21,000 rpm 
and washed with PBS buffer. 
4.5 In vitro detachment of HA shell 
To evaluate the glucose-responsive detachment of HA-PBA shell, 
HA-Fc-Liposomes or HA_CL-Fc-Liposomes containing rhodamine- 
labelled HA-PBA were incubated under pH 6.0 with different glucose 
concentrations (1, 5, 10, 20, and 50 mM) at 37 °C for 1 h. The detached 
Rho-HA-PBA were separated by centrifugation at 21,000 rpm. 
The fluorescence intensity of free Rho-HA-PBA was determined at 
575 nm with an excitation wavelength of 552 nm by a microplate 
reader (Infinite M200 PRO, Tecan). 
4.6 In vitro insulin release 
To evaluate the in vitro insulin release profile, FITC-insulin-loaded 
HA-Fc-Liposomes or Fc-Liposomes were suspended in Tris-HCl 
buffer (10 mM, pH 7.4) or Tris-HCl buffer (10 mM, pH 2.5). 
At prearranged time intervals, released insulin was harvested by 
centrifugation at 21,000 rpm. The fluorescence intensity of free FITC- 
insulin was determined at 519 nm with the excitation wavelength at 
495 nm. 
4.7 Cell culture 
Caco-2 cells were obtained from Tissue Culture Facility of UNC 
Lineberger Comprehensive Cancer Center and cultured in Dulbecco’s 
Modified Eagle’s Medium supplemented with 10% (v/v) fetal bovine 
serum (FBS), penicillin (100 U/mL) and streptomycin (100 μg/mL) 
in a 37 °C incubator (Thermal Scientific) under 5% CO2 and 90% 
humidity. The cells were regularly sub-cultured with trypsin-EDTA 
(0.25%, w/w) and cell density was determined with hemocytometer 
before each experiment. 
4.8 In vitro cytotoxicity 
The cytotoxicity of the HA-Fc-Liposomes and Fc-Liposomes 
were evaluated using 3-(4,5)-dimethylthiahiazo(-z-y1)-3,5-di- 
phenytetrazoliumromide (MTT) assay with Caco-2 cells. Prior to 
the test, the medium in 96-well plate was removed. After washing 
with PBS, serial dilutions of bare HA-Fc-Liposomes or Fc-Liposomes 
were added into wells. After 24 h incubation, thiazolyl blue solution 
(5 mg/mL) was added to each well and incubated for another 4 h. 
After removing the medium, the purple formazan crystal was dissolved 
in 150 μL of dimethyl sulfoxide (DMSO). The absorbance of the 
plates was read at 570 nm by a microplate reader. 
4.9 In vitro transcytosis studies 
To further investigate the transport of insulin-loaded liposomes 
across the epithelial cells, the Caco-2 cell monolayer was incubated 
for 21 days after being seeded on the Transwell plates (Costar). Prior 
to the studies, the medium was replaced with pre-warmed Hanks’ 
balanced salt solution (HBSS) (pH 6.0) in the apical chamber and 
HBSS (pH 7.4) in the basolateral chamber and allowed to equilibrate 
for 1 h at 37 °C. Afterwards, the apical solution was replaced with 
200 μL of FITC-insulin + glucose (10 mM), Ins-Liposomes + glucose 
(10 mM), Fc-Liposomes + glucose (10 mM), HA-Fc-Liposomes, 
HA-Fc-Liposomes + glucose (10 mM), and HA_CL-Fc-Liposomes + 
glucose (10 mM), respectively. After incubation for 2 h at 37 °C, the 
basolateral solution was collected and the amount of transported 
FITC-insulin was determined using a microplate reader at 519 nm 
with the excitation wavelength at 495 nm. 
4.10 Immunofluorescence staining 
Small intestine was harvested and fixed in 10% formalin. Then the 
tissues were embedded and cut into 8 μM thick sections. After 
rehydration, the slides were blocked and incubated with IgG or 
anti-mouse FcRn primary antibodies (Sigma Cat No. ABF191) 
overnight and then incubated with anti-rabbit secondary antibodies. 
The expression of FcRn was detected under fluorescence microscope. 
4.11 In vivo absorption 
The animal study protocol was approved by the Institutional Animal 
Care and Use Committee at North Carolina State University and 
University of North Carolina at Chapel Hill. STZ-induced adult 
diabetic mice (male C57B6, Jackson Lab, USA) were fasted for 6 h 
before administration. The mice were administered with the following 
formulations by oral gavage: Fc-Liposomes, HA-Fc-Liposomes, and 
HA_CL-Fc-Liposomes (4 mL/kg). After 30 min, the experiment 
group was further orally administered glucose solution (1 g/kg). 
The mice were euthanized and the duodenum tissue were collected 
for frozen section after 2 h. Hoechst 33342 was used for nuclei 
staining, and the cross sections of the tissue were observed by 
fluorescence microscope. 
4.12 In vivo studies using STZ-induced diabetic mice 
The in vivo efficacy of glucose-responsive insulin-loaded liposome 
for diabetes treatment was evaluated on STZ-induced adult diabetic 
mice (male C57B6, Jackson Lab, USA). Mouse glucose levels were 
monitored for two days before administration, and all mice were 
fasted for 6 h before administration. Mice (n = 5) were chosen per 
group such that the mean initial blood glucose levels were between 
300–500 mg/dL per group. Before the administration, HA-Fc- 
Liposomes were incubated under pH 6.0 with 10 mM glucose at 
37 °C for 1 h. The pre-treated HA-Fc-Liposomes were collected by 
centrifugation at 21,000 rpm. The mice were administered with the 
following formulations by oral gavage: insulin solution, Ins-Lipsomes, 
Fc-Liposomes, HA-Fc-Liposomes, and HA-Fc-Liposomes pre-treated 
with glucose (insulin dose: 10 U/kg). 
In order to assess the glucose-responsive intestinal absorption of 
liposomes by oral administration of glucose solution to simulate the 
postprandial condition, the mice were administered with the following 
formulations by oral gavage: insulin solution, Fc-Liposomes, HA- 
Fc-Liposomes, and HA_CL-Fc-Liposomes (insulin dose: 10 U/kg). 
After 30 min, the experiment group was further orally administered 
glucose solution (1 g/kg). The glucose levels of each mouse were 
monitored over time using the Clarity GL2Plus glucose meter (Clarity 
Diagnostics, Boca Raton, Florida, USA). The plasma insulin con-
centration was measured using InvitrogenTM NovexTM EASIATM Insulin 
Human ELISA Kit. 
4.13 Statistical analysis 
All results presented are Mean ± s. d. Statistical analysis was performed 
using two-tailed Student’s t-tests. *P value < 0.05 describing the 
differences between experimental groups and control groups was 
considered statistically significant. 
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